THE ‘OZEMPIC’ TRADE: Weight Loss Drugs, Market Cap Gains? A $100-billion global market, rising ‘diabesity’ in India, and a major patent cliff ahead. As semaglutide goes off patent, the race among Indian pharma companies to capture the GLP-1 opportunity  LinkedIn

Leave a Reply

Your email address will not be published. Required fields are marked *